Viatris Positive Top-Line Results from Phase 3 in Low Contrast Visual Disturbances

 MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo

Results Showed Patient-Reported Functional Benefit in Treating Significant Chronic Night Driving Impairment in Keratorefractive Patients With Reduced Mesopic Vision, a Condition With No Current FDA-Approved Therapies

No Evidence of Tachyphylaxis Was Observed In This Study Over The 6-Week Period

Study Was Conducted Under FDA Special Protocol Assessment And Fast-Track Designation

https://finance.yahoo.com/news/viatris-announces-positive-top-line-120000338.html